 TRACON Pharmaceuticals Inc. has entered into a collaborative partnership agreement with China-based Eucure Biopharma for the development of CTLA-4 antibody YH001 in multiple oncology indications, including soft tissue sarcoma. Under the terms of the agreement, TRACON said it will be responsible for the clinical development and commercialization of YH001 in North America, with the majority of the development activities expected to occur in the US. 